Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bukowski

Showing results (111-120 of 159) with videos related to

Pageof 16
Sort By:
Clinical Pharmacology and Therapeutics|March 7, 2007
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha familyP Masci, T Olencki, L Wood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinomaR J Motzer, A Rakhit, L H Schwartz, et al.
Blood|August 8, 1998
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalphaW Ling, P Rayman, R Uzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancerR L Schilsky, R Bukowski, H Burris, et al.
Cancer Research|October 15, 1994
T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary reportX Li, J Liu, J K Park, et al.
Investigational New Drugs|November 15, 2006
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumorsS Kalmadi, M Davis, A Dowlati, et al.
Medical Oncology (Northwood, London, England)|September 17, 2009
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGETS Negrier, E Jäger, C Porta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
The T cell death knell: immune-mediated tumor death in renal cell carcinomaR G Uzzo, V Kolenko, C J Froelich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumorsS Kaul, L N Igwemezie, D J Stewart, et al.
Investigational New Drugs|January 1, 1996
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphomaS L Allen, L P Schacter, S M Lichtman, et al.
Pageof 16

Showing results (111-120 of 159) with videos related to

Sort By:
Pageof 16
Clinical Pharmacology and Therapeutics|March 7, 2007
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha familyP Masci, T Olencki, L Wood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinomaR J Motzer, A Rakhit, L H Schwartz, et al.
Blood|August 8, 1998
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalphaW Ling, P Rayman, R Uzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancerR L Schilsky, R Bukowski, H Burris, et al.
Cancer Research|October 15, 1994
T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary reportX Li, J Liu, J K Park, et al.
Investigational New Drugs|November 15, 2006
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumorsS Kalmadi, M Davis, A Dowlati, et al.
Medical Oncology (Northwood, London, England)|September 17, 2009
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGETS Negrier, E Jäger, C Porta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
The T cell death knell: immune-mediated tumor death in renal cell carcinomaR G Uzzo, V Kolenko, C J Froelich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumorsS Kaul, L N Igwemezie, D J Stewart, et al.
Investigational New Drugs|January 1, 1996
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphomaS L Allen, L P Schacter, S M Lichtman, et al.
Pageof 16